Anemia Management Algorithm for Chronic Kidney Failure
(SMART Trial)
Trial Summary
What is the purpose of this trial?
This is a human subject research study conducted in patients undergoing dialysis treatment with darbepoetin alfa at Intermountain Utah Dialysis and Intermountain Medical Center Dialysis Services. The purpose is to test a dose recommendation algorithm that may reduce hemoglobin variability and drug cost.
Research Team
Chemiti Gopal, MD
Principal Investigator
Intermountain Health Care, Inc.
Eligibility Criteria
This trial is for adults with End Stage Kidney Disease on hemodialysis who have stable anemia management, without hospitalization for the last 150 days. It's not for those with high inflammation, active cancer, severe parathyroid issues, different anemia treatments than Aranesp, recent GI bleeding or relevant hospitalizations.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive model-based Aranesp doses calculated by the algorithm instead of standard care procedures
Follow-up
Participants are monitored for safety and effectiveness after treatment, focusing on hemoglobin levels and drug administration
Treatment Details
Interventions
- Algorithm model-based Aranesp doses
- Standard of care
Find a Clinic Near You
Who Is Running the Clinical Trial?
Intermountain Health Care, Inc.
Lead Sponsor